Kyverna Therapeutics, Inc. Common Stock

KYTX XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

480M

Short interest (May 15)

8.7%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.52%

↓ 6.4%

Available Shares

400K

↓ 54.6%

Price Chart

Company Overview

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001994702

Asset Type: CS

Market Data

Market Cap: $480,282,174

Employees: 129

Status: Active

Short Interest

Current Borrow Fee 0.52%

Range: 0.43% - 0.52%

Available Shares 400K

Range: 100K - 400K

Recent Changes

Fee Change: ↑ 10.4%

Available Change: ↓ 6.3%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime